Octant, Inc.

Octant, Inc. is a US-based biotechnology company focused on developing advanced small molecules to modulate complex cellular mechanisms related to disease, enhancing drug discovery processes for biopharmaceutical firms. Founded in 2017 in Tukwila, US, Octant, Inc. specializes in biotechnology solutions.

The company has secured funding through five deals, with the latest being a Series B round on April 21, 2022, amounting to USD 80. 00 mn. The funding was led by Catalio Capital Management alongside several prominent investors including Andreessen Horowitz and Bristol-Myers Squibb Company. Co-founders Ramsey Homsany, Ryan Pijai, and Sri Kosuri play significant roles in the company, with Ryan Pijai and Sri Kosuri serving as Co-CEOs.

Octant specializes in the development of next-generation small molecules aimed at modulating complex cellular mechanisms that drive diseases, particularly those related to protein misfolding and mistrafficking. The company's innovative approach integrates advanced synthetic biology and high-throughput chemistry to create custom sensors within human cells, allowing for detailed modeling of cellular functions and disease mechanisms. This technology facilitates the identification of how drug candidates interact with specific proteins and affect cellular outcomes. Octant primarily serves biopharmaceutical companies engaged in drug discovery and development across various geographical markets, including North America, Europe, and Asia.

Their offerings are positioned to enhance the efficiency and accuracy of drug development processes for a diverse client base, ranging from large pharmaceutical firms to emerging biotech companies. Octant's revenue model is structured around B2B partnerships and collaborations with pharmaceutical companies seeking to leverage their advanced drug discovery technologies. The company engages in transactions that typically involve contractual agreements for access to its proprietary platforms and datasets, tailored to client-specific drug development needs. Clients may participate in long-term partnerships that provide them with ongoing access to Octant’s high-throughput drug discovery capabilities, potentially under subscription agreements or project-based contracts.

Specific pricing plans and terms are negotiated based on the scope and scale of engagement, which may include milestone-based payments associated with the advancement of drug candidates through various stages of development. The revenue generated through these collaborations underscores the value delivered to clients in accelerating their drug discovery timelines and improving therapeutic outcomes. In April 2022, Octant, Inc. raised USD 80.

00 mn in Series B funding led by Catalio Capital Management, with participation from other investors including Bristol-Myers Squibb Company and Andreessen Horowitz. The funding will be utilized to further develop Octant's product offerings and invest in research and development of drugs. The company is focusing on expanding its reach into more global markets and aims to enhance its capabilities in creating advanced small molecules for drug discovery.